Gauthier Alex G, Wu Jiaqi, Lin Mosi, Sitapara Ravikumar, Kulkarni Abhijit, Thakur Ganesh A, Schmidt Edward E, Perron Jeanette C, Ashby Charles R, Mantell Lin L
Department of Pharmaceutical Sciences, College of Pharmacy and Health Sciences, St. John's University, Queens, New York, NY 11439, USA.
Department of Pharmaceutical Sciences, Northeastern University, Boston, MA 02115, USA.
Antioxidants (Basel). 2021 Jan 19;10(1):135. doi: 10.3390/antiox10010135.
Supplemental oxygen therapy with supraphysiological concentrations of oxygen (hyperoxia; >21% O) is a life-saving intervention for patients experiencing respiratory distress. However, prolonged exposure to hyperoxia can compromise bacterial clearance processes, due to oxidative stress-mediated impairment of macrophages, contributing to the increased susceptibility to pulmonary infections. This study reports that the activation of the α7 nicotinic acetylcholine receptor (α7nAChR) with the delete allosteric agonistic-positive allosteric modulator, GAT107, decreases the bacterial burden in mouse lungs by improving hyperoxia-induced lung redox imbalance. The incubation of RAW 264.7 cells with GAT107 (3.3 µM) rescues hyperoxia-compromised phagocytic functions in cultured macrophages, RAW 264.7 cells, and primary bone marrow-derived macrophages. Similarly, GAT107 (3.3 µM) also attenuated oxidative stress in hyperoxia-exposed macrophages, which prevents oxidation and hyper-polymerization of phagosome filamentous actin (F-actin) from oxidation. Furthermore, GAT107 (3.3 µM) increases the (1) activity of superoxide dismutase 1; (2) activation of Nrf2 and (3) the expression of heme oxygenase-1 (HO-1) in macrophages exposed to hyperoxia. Overall, these data suggest that the novel α7nAChR compound, GAT107, could be used to improve host defense functions in patients, such as those with COVID-19, who are exposed to prolonged periods of hyperoxia.
使用超生理浓度氧气(高氧;>21% O)进行补充氧疗是对呼吸窘迫患者的一种挽救生命的干预措施。然而,长时间暴露于高氧环境会损害细菌清除过程,这是由于氧化应激介导的巨噬细胞功能受损,导致肺部感染易感性增加。本研究报告称,使用变构激动剂-正变构调节剂GAT107激活α7烟碱型乙酰胆碱受体(α7nAChR),可通过改善高氧诱导的肺氧化还原失衡来降低小鼠肺部的细菌负荷。用GAT107(3.3 μM)孵育RAW 264.7细胞可挽救培养的巨噬细胞、RAW 264.7细胞和原代骨髓来源巨噬细胞中高氧损害的吞噬功能。同样,GAT107(3.3 μM)也可减轻高氧暴露巨噬细胞中的氧化应激,从而防止吞噬体丝状肌动蛋白(F-肌动蛋白)氧化和过度聚合。此外,GAT107(3.3 μM)可增加暴露于高氧的巨噬细胞中(1)超氧化物歧化酶1的活性;(2)Nrf2的激活以及(3)血红素加氧酶-1(HO-1)的表达。总体而言,这些数据表明,新型α7nAChR化合物GAT107可用于改善长时间暴露于高氧环境的患者(如COVID-19患者)的宿主防御功能。